Caplacizumab (Cablivi) for iTTP

October 19, 2020

Issue #: 


Caplacizumab-yhdp (Cablivi – Sanofi /Genzyme), a
von Willebrand factor-directed antibody fragment, has
been approved by the FDA for use in combination with
plasma exchange and immunosuppressive therapy
for treatment of immune-mediated thrombotic
thrombocytopenic purpura (iTTP; formerly called
acquired thrombotic thrombocytopenic purpura
[aTTP]) in adults. It is the first drug to be approved in
the US for this indication.